Elevaire Systems
← Back to Insights
Industry Insightsmanaged securityaccess managementsecurity

Protecting Research Data and IP at a Growing Life Sciences Company

Elevaire Systems·

A 70-person biotech has two years of assay results, a compound library and the protocols behind its lead program spread across a shared drive, an electronic lab notebook, a few instrument PCs and a cloud folder shared with its contract research organization. A senior scientist gives notice on a Friday and starts at a competitor two weeks later. Nobody can say with confidence what that scientist downloaded, forwarded or synced in the meantime.

For most growing life sciences companies, the research data is the company. It is what investors are paying for, what a future partner will license, and what a competitor would most like to have. This post covers where that data actually leaks, why it happens at companies of this size, what it costs, and the controls that protect it without slowing the science down.

Why research data is the asset worth protecting

Patient records get most of the attention in healthcare security, and for good reason. But a preclinical or early clinical company often holds very little patient data. What it holds instead is harder to replace: experimental results, formulations, manufacturing processes, regulatory strategy, and years of negative results that tell a competitor which paths not to take.

Its value rarely shows up on a balance sheet until a deal is priced or a competitor files something uncomfortably familiar. Once a trade secret is out, there is no restoring it from backup.

The U.S. government treats this as a national concern. The National Counterintelligence and Security Center lists the bioeconomy among the critical technology sectors it works to protect, and in July 2024 it joined military counterintelligence partners in a bulletin warning emerging technology startups that some foreign investors seek proprietary data under the label of due diligence.

How research data actually walks out the door

Most loss at a company this size does not start with a sophisticated attack. It starts with ordinary access that nobody narrowed down as the company grew.

Departing employees. This is the pattern that shows up again and again in federal trade secret cases. In 2021, federal prosecutors in New Jersey charged a former director at a pharmaceutical company with emailing proprietary research documents from his work account to personal Gmail and Yahoo accounts around the time he left for a competitor. In an earlier case, prosecutors in San Francisco charged four former Genentech employees with taking confidential documents to help a biosimilar competitor. Neither case required hacking.

Partners and contractors. Contract research organizations, contract manufacturers, academic collaborators and consultants all need some of your data. The risk is that "some" quietly becomes "all" because a shared folder was easier than a scoped one, and nobody revisits the share when the project ends. The 2025 Verizon Data Breach Investigations Report found that third-party involvement in breaches doubled to 30% year over year.

Investors and prospective partners. Fundraising and business development mean opening a data room. The NCSC bulletin specifically warns that requests for proprietary detail during "due diligence" can be a collection tactic. A data room with download rights, no watermarking and no expiry date is an open door.

Outside attackers. Life sciences companies face the same phishing, business email compromise and ransomware as every other business, with a higher payoff for the attacker if research data is in reach. IBM's Cost of a Data Breach research puts the average pharmaceutical industry breach at $4.61 million in its 2025 edition and about $5.25 million in 2026. Those are averages across company sizes, but even a fraction of that is a serious hit for an R&D-funded company.

Instruments and lab systems. Instrument control PCs often run older operating systems the vendor will not let you update, sit on the same network as everyone's laptops, and store raw data locally. They are easy to forget and hard to patch, which makes them an easy foothold.

Why this shows up at growing companies

At 15 people, everyone is on every project and access to everything is the practical default. At 70 or 150 people, that same default means a new contractor in the quality team can open the regulatory strategy folder, and a scientist who moved off a program two years ago still has full rights to its data.

A few patterns make this worse in life sciences specifically:

  • Data lives in many places. Electronic lab notebooks, LIMS, instrument PCs, cloud storage, email attachments and personal drives all hold pieces of the record.
  • Collaboration is constant. Partners, CROs and academic groups come and go with each program, and each one gets access that is rarely removed on schedule.
  • IT is usually outsourced and stretched. The IT provider keeps laptops working and accounts created. Deciding who should see which research data, and watching for unusual downloads, often falls between IT, lab operations and leadership without a clear owner.
  • Regulated and unregulated data mix. GxP records, clinical data and pure research data often share the same storage, with the strictest data protected no better than the rest.

None of this is carelessness. It is what happens when a company outgrows its access model.

Where research data lives and what protects it

Where it livesCommon gapControl that fixes it
Shared drives and cloud storageCompany-wide access by defaultProgram-based groups, quarterly access review
Electronic lab notebook and LIMSFormer project members keep rightsRole-based access tied to the HR system
Partner and CRO sharesLinks never expireScoped shares with end dates
Investor data roomsUnlimited downloadsView-only, watermarking, expiry
Instrument PCsUnpatched, on the main networkNetwork segmentation, allowlisting, backup
EmailForwarding to personal accountsAuto-forward blocks, data loss rules

The controls that protect research data

Protecting IP does not mean locking scientists out of their own work. It means deciding who needs what, enforcing it in the tools you already use, and watching for the signals that matter.

1. Know what you are protecting. Start with a short list: the crown-jewel data for each program, where it lives, and who owns it. A one-page inventory that leadership agrees on is enough to drive every decision below.

2. Organize access by program, not by person. Create groups per program or project in Microsoft 365 or Google Workspace and grant storage and ELN access to groups. When someone moves programs or leaves, one group change updates everything. Review membership quarterly.

3. Require multi-factor sign-in everywhere research data lives. That includes the ELN, LIMS, cloud storage and any partner portal, not only email. A stolen password should not be enough to reach a compound library.

4. Block the easy exits. Turn off automatic email forwarding to outside domains. Restrict external sharing to approved partner domains. Limit sync of research folders to managed company devices, and use device management so a lost or departing laptop can be wiped.

5. Watch for unusual data movement. Large downloads, mass file syncs, new forwarding rules and sharing to personal accounts are the signals that preceded the trade secret cases above. Microsoft 365 and Google Workspace both log these events. Someone has to actually review them, especially in the weeks before and after a resignation.

6. Build offboarding around data, not just accounts. When a researcher gives notice, review their recent file activity, confirm company data on personal devices is removed, and disable access on the last day, including partner portals and instrument logins that are not tied to the main directory.

7. Scope every external share. Give CROs and collaborators access to the specific folders a project needs, with an end date. Use view-only data rooms with watermarking for investors and potential partners, and log every download.

8. Segment and protect lab systems. Put instrument PCs on their own network segment, use application allowlisting where they cannot be patched, and back up their local data to a location attackers cannot encrypt.

9. Write it down. Leadership should agree on an acceptable use policy, a data handling standard for partners, and an incident response plan that covers suspected IP theft, including when to involve counsel and when to contact the FBI. The FBI accepts reports of suspected trade secret theft through local field offices and tips.fbi.gov.

How a managed security approach handles it

Most growing life sciences companies already have an IT provider. What they lack is someone whose job is security: setting the access model, running the controls, and watching the signals.

Elevaire Managed Security works alongside the existing IT provider or internal team. Elevaire manages the security tools, enforces multi-factor sign-in and access hardening, runs email security and device management, applies application allowlisting, and watches for threats. The Plus and Complete packages add 24/7 detection and response, identity monitoring and backup, so a mass download at 2 a.m. or a suspicious sign-in from a new country gets looked at the same night. A quarterly security review keeps access and sharing in line as programs and partners change.

For the decisions above the tool level, a virtual CISO sets the data handling policies, reviews partner and CRO security, prepares leadership and board reporting, and runs tabletop exercises so the team has rehearsed a suspected IP theft before it happens.

Example engagement: a 90-person med tech company is preparing for a Series B and a co-development deal with a larger device maker. Elevaire would inventory where design files and test data live, move access to program-based groups, block forwarding to personal accounts, set up a view-only data room with download logging for the diligence process, and review the partner's security questionnaire responses before any files are shared.

More on the specific pressures in this sector is on our pharma, med tech and life sciences page.

Frequently Asked Questions

How do biotech companies protect intellectual property from employees who leave?

Organize access by program so people only hold the data they need, block automatic forwarding and personal-account sharing, and review file activity when someone gives notice. Disable all access on the last day, including partner portals and instrument logins.

How much does research data protection cost for a small life sciences company?

Elevaire Managed Security is offered at predictable monthly pricing with no hourly billing, scaled to team size and package. For context, IBM's research puts the average pharmaceutical industry breach between $4.61 million and $5.25 million across its 2025 and 2026 reports. Most of the controls in this post use features already in Microsoft 365 or Google Workspace, so the main cost is the time to configure and monitor them.

Does Elevaire replace our IT provider or lab IT team?

No. Elevaire works alongside your existing IT provider or internal team. They keep handling laptops, accounts and day-to-day support, and Elevaire handles security: access design, monitoring, response and policy. If you have no IT support at all, the Complete package brings in a vetted IT partner for help desk.

What should we do if we think a former employee took research data?

Preserve evidence first: do not wipe their laptop or delete their accounts until logs and file activity are captured. Then involve legal counsel, review sharing and download logs, and revoke any remaining access. Counsel can advise on civil remedies and whether to report to the FBI, which handles federal trade secret cases.

Do we need to meet a specific framework to protect research IP?

Not necessarily. Research IP protection is mostly about access control, monitoring and offboarding, which no single framework mandates for a private company. If you also handle clinical data, sell to the federal government or face partner security reviews, HIPAA, SOC 2 or CMMC may apply, and the same controls carry over.

How do we get started?

Begin with a one-page inventory of your most valuable research data, where it lives and who can reach it today. That exercise alone usually shows where the largest gaps are. From there, prioritize multi-factor sign-in, program-based access and forwarding blocks before moving on to monitoring and partner controls.

About Elevaire Systems

Elevaire Systems is a managed security services provider for growing companies. We run your security tools and vendors, watch for threats and stop attacks for one predictable monthly price, with virtual CISO leadership and compliance readiness when you need more.

See Where Your Security Stands

Take the free 3-minute scorecard for your top security risks, or book a 30-minute Risk Snapshot to talk it through.